Gilead Sciences, Inc. European Marketing Application for Boosting Agent Cobicistat

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the Marketing Authorisation Application (MAA) for cobicistat, submitted on April 26, 2012, has been validated by the European Medicines Agency (EMA). Cobicistat is Gilead’s pharmacoenhancing or “boosting” agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing. Currently, ritonavir is the only agent used to boost HIV therapy. Review of the MAA for cobicistat will be conducted under the centralized licensing procedure, which, when finalized, provides one marketing authorization in all 27 member states of the European Union (EU).